{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-042537","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.533309+00:00","generated_at":"2026-05-30T22:17:22.403402+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PDS Biotech: 84.4% 36-month OS in cervical cancer trial of Versamune HPV + chemoradiation","bullets":["36-month OS rate 84.4% (all patients) vs ~64% historical; 100% in 8 patients receiving all 5 doses.","36-month PFS rate 74.9% overall, 100% in fully dosed subgroup; historical ~61%.","Complete metabolic response (CMR) in 88% (15/17) of patients at 4 months per PET.","Versamune HPV well-tolerated; most common related AE injection site reaction (71%).","Median follow-up 19 months; data presented at ASTRO 2024, awarded Basic/Translational Science Award."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-042537","json":"https://secwatch.observer/filing/0001140361-24-042537.json","markdown":"https://secwatch.observer/filing/0001140361-24-042537.md","text":"https://secwatch.observer/filing/0001140361-24-042537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/0001140361-24-042537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036124042537/ef20036539_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:17:22.403402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}